U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
RegulatoryapprovedOnswikPositive
AI Analysis
Summary
The FDA has approved Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for treating type 2 diabetes in adults, designed to reduce injections by over 300 per year compared to once-daily basal insulin.
Outcome Details
FDA approval for Onswik (insulin efsitora alfa-gobe) as a once-weekly basal insulin injection for adults with type 2 diabetes
Importance:8/10
Sentiment:
0.95
FDA approvaltype 2 diabetesbasal insulinonce-weeklyLillynew drug
Related Companies
Read the original article
Published by PR Newswire Biotech on September 24, 2026 10:45 AM